NEW YORK, May 26, 2026, 11:03 EDT
- Sanara MedTech was last down roughly 2.1% at $22.69 on the Nasdaq in late-morning trading.
- U.S. equities pushed higher after the Memorial Day holiday, but SMTI lagged the main indexes.
- Sanara investors have been trading on the company’s May 11 Q1 report, after it reported higher revenue and swung back to profit.
Sanara MedTech Inc. traded lower Tuesday, even as the broader U.S. market moved up. The stock was at $22.69 at 10:38 a.m. EDT, down 48 cents since Friday’s close. Around 4,010 shares changed hands. Investors are still looking at the company’s latest swing to profit and weighing its spending plans.
Market hours are in focus as U.S. equity trading resumed after Memorial Day. Nasdaq’s calendar listed May 25 as a holiday, with normal trading from 9:30 a.m. to 4 p.m. Eastern.
S&P 500 was up 0.8% and the Nasdaq Composite jumped 1.3% near 10:15 a.m. Eastern, AP reported, with the major indexes getting a lift as U.S. markets caught up to global gains from Monday. The broader tape wasn’t the issue.
Sanara didn’t issue a new update Tuesday morning, with its investor-relations page still showing the May 11 Q1 results as the most recent announcement. That kept trading focused on the last earnings report, guidance, and the usual light volume.
Sanara MedTech Inc. reported first-quarter net revenue up 19% to $27.8 million. Gross profit was $25.9 million, or 93% of revenue. The Fort Worth, Texas-based company had net income from continuing operations of $0.4 million, or 4 cents a diluted share, after a loss last year.
Sanara president and CEO Seth Yon said on the May 12 investor call that the quarter topped expectations, marking the first full period where the company focused only on the surgical market. Yon said soft-tissue repair products like CellerateRX and BIASURGE drove revenue growth.
Sanara MedTech left its outlook for 2026 revenue unchanged at $116 million to $121 million, pointing to growth of roughly 13% to 17%. For Q2, the company expects revenue between $28.5 million and $29.5 million.
Sanara’s shares are lagging after its profit swing, as investors looked past the turnaround. The 10-Q showed cash dropped to $13.6 million on March 31 from $16.6 million at the end of the year. Long-term debt was $46.2 million. Other expense climbed, mostly from higher interest and fees on the CRG term loan, plus losses from an equity-method investment.
Sanara’s CFO Elizabeth Taylor said on the call the company used cash to cover its full quarterly debt service. She described it as “a milestone” for Sanara and linked it to better free cash flow. Free cash flow is what’s left after operations and capital expenses; investors watch it to see if a company can finance growth without new capital. Investing
Adjusted EBITDA jumped 58% to $4.3 million, stripping out interest, taxes, depreciation and amortization. That boost supports the bulls, but Sanara’s balance sheet remains a problem. The company still needs cash for sales growth, R&D, and product launches, and it has debt.
Surgical and wound-care stocks traded mixed. Organogenesis Holdings lost roughly 2.1%. MiMedx Group added around 1.4%. Integra LifeSciences was down about 1.3%. The iShares U.S. Medical Devices ETF slipped a little.
Sanara draws coverage from Cantor Fitzgerald, H.C. Wainwright and Lake Street Capital Markets. Analyst Frank Takkinen at Lake Street kept his buy call and $32 target after Sanara’s first-quarter results, a May 12 note summary said. Analyst coverage is still sparse.
Tuesday’s drop could mean more than a random move. Hospital budget pressure might slow down uptake, while new sales reps could take longer before making a measurable impact, and higher interest costs may keep squeezing operating gains. That would leave Sanara’s profit turnaround looking shaky. Yon told investors hospitals are still weighing operating-room spending, but he added the company thinks it is well placed on clinical evidence, economic evidence, and price.
